PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.60%
Negative revenue growth while AVGO stands at 1.98%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-11.98%
Negative gross profit growth while AVGO is at 1.36%. Joel Greenblatt would examine cost competitiveness or demand decline.
-37.94%
Negative EBIT growth while AVGO is at 10.07%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-37.94%
Negative operating income growth while AVGO is at 10.07%. Joel Greenblatt would press for urgent turnaround measures.
-34.92%
Negative net income growth while AVGO stands at 9.66%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-34.25%
Negative EPS growth while AVGO is at 10.17%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-34.25%
Negative diluted EPS growth while AVGO is at 8.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.72%
Share count expansion well above AVGO's 0.41%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.82%
Diluted share count expanding well above AVGO's 0.40%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
67.96%
Similar OCF growth to AVGO's 67.97%. Walter Schloss would assume comparable operations or industry factors.
77.88%
FCF growth 50-75% of AVGO's 125.40%. Martin Whitman would see if structural disadvantages exist in generating free cash.
66.43%
10Y revenue/share CAGR above 1.5x AVGO's 20.27%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
1.43%
5Y revenue/share CAGR under 50% of AVGO's 20.27%. Michael Burry would suspect a significant competitive gap or product weakness.
74.20%
3Y revenue/share CAGR above 1.5x AVGO's 38.52%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
650.77%
10Y OCF/share CAGR above 1.5x AVGO's 64.06%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
66.63%
5Y OCF/share CAGR is similar to AVGO's 64.06%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
1918.95%
3Y OCF/share CAGR above 1.5x AVGO's 348.39%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
38.55%
Below 50% of AVGO's 668.43%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-33.64%
Negative 5Y net income/share CAGR while AVGO is 668.43%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
169.09%
Below 50% of AVGO's 826.36%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
371.99%
10Y equity/share CAGR above 1.5x AVGO's 169.79%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
93.18%
5Y equity/share CAGR at 50-75% of AVGO's 169.79%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
52.23%
Below 50% of AVGO's 123.14%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.46%
Firm’s AR is declining while AVGO shows 8.79%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
6.48%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
9.12%
Asset growth above 1.5x AVGO's 5.41%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.59%
50-75% of AVGO's 5.25%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-2.32%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
4.04%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-2.23%
We cut SG&A while AVGO invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.